Internal Medicine News - Haloperidol may raise risk of heart arrhythmia
Patients taking the antipsychotic drug haloperidol may be at increased risk for heart rhythm abnormalities, according to a Food and Drug Administration alert.
Revised labeling on the drug, marketed as Haldol, Haldol decanoate, and Haldol lactate, includes a cardiovascular subsection explaining the increased risk for prolonging the QT interval. The risk for arrhythmia appears to be greater when the drug is given in doses above the recommended amounts, or when it is given intravenously. The FDA advises clinicians to review the cardiac histories of patients who take haloperidol.
Related Results
HaldolTrust, E-innovation and Leadership in ChangeForeign Banks in United States Since World War II: A Useful FringeBuilding Your Brand With Brand Line ExtensionsThe Impact of the Structure of Debt on Target Gains
For more information, contact the FDA by visiting www.fda.gov/medwatch/safety/2007/safety07.htm#Haloperidol.
COPYRIGHT 2008 International Medical News Group
COPYRIGHT 2008 Gale, Cengage Learning
